MiRNA Regulation of MIF in SLE and Attenuation of Murine Lupus Nephritis With miR-654
Authors:
Open Access
- 19 September 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 2229
Abstract
Objective: Macrophage Migration Inhibitory Factor (MIF) is involved in the pathogenesis of systemic lupus erythematosus (SLE) and lupus nephritis (LN). MicroRNAs (miRNAs) play important roles in LN but whether specific miRNAs regulate the expression of MIF in LN is unknown. We explore specific miRNAs that can regulate MIF expression, and investigate miR-654 for the treatment of experimentally-induced murine lupus nephritis. Methods: Sera samples from 24 SLE patients and 24 controls were collected to measure the MIF concentration and its correlation with disease activity. A luciferase reporter assay was used to explore the target of miR-654. ELISA was used to detect the downstream cytokines regulated by miR-654 and MIF. Western blot was applied to measure the impact of miR-654 inhibition on downstream MIF signaling. The therapeutic efficacy of miR-654 was tested in the pristine-induced lupus mouse model. We further measured miR-654 expression and analyzed its relationship with MIF expression in SLE patients. Results: The serum MIF level was increased in SLE patients (p < 0.001) and positively correlated with the SLEDAI score (r = 0.5473; p = 0.0056). MiR-654 inhibited MIF and downstream inflammatory cytokine production by selectively inhibiting the phosphorylation of ERK and AKT. Activation of miR-654 reduced IL-1β, IL-6, IL-8, and TNF-α production, reduced gomerulonephritis, and decreased MIF, IgG, and C3 expression in murine lupus glomeruli. Furthermore, MIF was negatively correlated with miR-654 expression (r = −0.4644; p = 0.0222) in SLE patients. Conclusion: MiR-654 negatively correlated with MIF and disease activity in patients with SLE. MiR-654 inhibits MIF expression via binding to MIF 3'UTR, selectively suppresses the phosphorylation of ERK and AKT, and reduces downstream inflammatory cytokine production. In vivo miR-654 treatment decreases MIF and downstream cytokine production and ameliorates murine lupus nephritis.Keywords
This publication has 36 references indexed in Scilit:
- MIF functional polymorphisms (-794 CATT5-8 and -173 G>C) are associated with MIF serum levels, severity and progression in male multiple sclerosis from western Mexican populationJournal of Neuroimmunology, 2018
- Redefining lupus nephritis: clinical implications of pathophysiologic subtypesNature Reviews Nephrology, 2017
- Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trialAnnals of the Rheumatic Diseases, 2017
- New insights into the immunopathogenesis of systemic lupus erythematosusNature Reviews Rheumatology, 2016
- Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosusScientific Reports, 2016
- Genetics and novel aspects of therapies in systemic lupus erythematosusAutoimmunity Reviews, 2015
- Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosusArthritis & Rheumatism, 2011
- The Macrophage Migration Inhibitory Factor-Glucocorticoid Dyad: Regulation of Inflammation and ImmunityMolecular Endocrinology, 2007
- Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity againstSalmonella typhimuriumProceedings of the National Academy of Sciences, 2002
- An essential regulatory role for macrophage migration inhibitory factor in T-cell activation.Proceedings of the National Academy of Sciences, 1996